Alendronate Conjugate for Targeted Delivery to Bone-Forming Prostate Cancer
J. Damasco, G. Yu, A. Kumar, R. C. Lirag, E. Whitley, S.-H. Lin, M. P. Melancon
This paper develops a Cy5.5-alendronate conjugate for targeted drug delivery to bone-forming prostate cancer metastases, showing enhanced bone targeting and reduced systemic circulation.
bioRxiv · Sep 26, 2022Biochemistry